Drug Profile
Acolbifene - Endoceutics
Alternative Names: Acolbifene hydrochloride; EM 652.HCl; EM-652; SCH 57068; SCH 57068.HClLatest Information Update: 11 Jul 2019
Price :
$50
*
At a glance
- Originator Endoceutics
- Developer Endoceutics; National Cancer Institute (USA)
- Class Antineoplastics; Benzopyrans; Osteoporosis therapies; Phenyl ethers; Piperidines
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 11 Jul 2019 Phase III development for Breast cancer is ongoing in Canada (Endoceutics pipeline, July 2019)
- 09 Oct 2015 No recent reports on development identified - Phase-II for Breast cancer (Prevention) in USA (PO)
- 23 Jul 2015 Further phase III development for Breast cancer is pending as Endoceutics seeks a partner for out-licensing